Table 1 Characteristics of patients
From: Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis
| Â | Sixty-four patients | Â | Â | Ninety-one pregnancies (%) |
|---|---|---|---|---|
Mean ± SD |  | Outcome of pregnancy | normal birth | 73 (80.2) |
 Age at diagnosis (years) | 23.95±5.56 |  | premature birth | 2 (2.2) |
 Disease duration (years) | 7.22±6.21 |  | spontaneous abortion | 8 (8.8) |
 Age at pregnancy (years) | 32.25±4.36 |  | therapeutic termination | 8 (8.8) |
Extent of UC n (%) | Â | Receiving treatment for UC | Â | Â |
 Total colitis | 30 (46.9) | at the onset of pregnancy | total (n=80) | 50 (62.5) |
 Left-side colitis | 22 (34.4) |  | salazosulfapyridine (SASP) | 20 (40) |
 Proctitis | 12 (18.7) |  | 5-aminosalicylic acid |  |
Clinical course n (%) | Â | Â | compound (5-ASA) | 19 (38) |
 Relapsing-remitting type | 53 (82.8) |  | SASP+prednisolone (PSL) | 5 (10) |
 Cronic continuous type | 6 (9.4) |  | 5-ASA+PSL | 3 (6) |
 Acute fulminating type | 1 (1.6) |  | 5-ASA+azathioprine | 1 (2) |
 First attack type | 4 (6.2) |  | PSL | 2 (4) |